Form 4: Apogee Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., sold 5,500 shares of common stock on August 5, 2026 for $134.17 per share.
Summary
- Option exercise/conversion: acquired 4,125 Common Stock at $22.86 ($94,298) on August 5, 2026; holds 173,998 after (Direct).
- Open-market sale: disposed of 5,500 Common Stock at $134.17 ($737,935) on August 5, 2026; holds 168,498 after (Direct).
- Option exercise/conversion: disposed of 4,125 Stock Option (Right to Buy) on August 5, 2026; holds 110,665 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $737,935 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Carl Dambkowski — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-05 | Option exercise/conversion | Common Stock | 4,125 | $23 | $94.3K | 173,998 |
| 2026-08-05 | Open-market sale | Common Stock | 5,500 | $134 | $737.9K | 168,498 |
| 2026-08-05 | Option exercise/conversion | Stock Option (Right to Buy) | 4,125 | — | — | 110,665 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-05 | Option exercise/conversion (4,125 shares) |
| 2026-08-05 | Open-market sale (5,500 shares) |
| 2026-08-05 | Option exercise/conversion (4,125 shares) |
Keywords
insider transaction, Form 4, APGE, Apogee Therapeutics, Inc., bearish, Carl Dambkowski
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.